Poecistasin
48-aa antistasin-type single-domain serine protease inhibitor from Poecilobdella manillensis — anticoagulant + anti-ischemic-stroke preclinical activity (Tang 2018).
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- 48-aa antistasin-type single-domain serine protease inhibitor from Poecilobdella manillensis — anticoagulant + anti-ischemic-stroke preclinical activity (Tang 2018).
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Poecistasin's preclinical anticoagulant + ischemic stroke benefits do NOT establish clinical efficacy in humans. No FDA-approved derivative exists; P. manillensis is not the FDA-cleared K040187 medicinal leech species.
Molecular Profile
- Category
- Proteinase Inhibitor
- Evidence tier
- Preclinical
- Molecular weight
- 5,300 Da
- Source species
- Poecilobdella manillensis
- Discovered
- 2018 · Tang X et al.
Biological Targets
- → factor XIIa
- → kallikrein
- → trypsin
- → elastase
Key Citations
- Tang X et al. (2018), Toxins (Basel) · PMID 30373118
External Resources
Related Proteinase Inhibitor Compounds
Hirustasin
Serine proteinase inhibitor targeting tissue kallikrein — anti-inflammatory pathway.
Eglin C
Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.
Bdellin B3
Kazal-type proteinase inhibitor targeting trypsin and plasmin — modulates inflammatory cascade.
LDTI (Leech-Derived Tryptase Inhibitor)
Selective inhibitor of human mast cell tryptase — anti-inflammatory pathway.